Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: A prospective cohort study using R2-MRI-measured liver iron content

Blood

Volumn 122, Issue 9, 2013, Pages 1678-1684

  Trottier, Bryan J ^a   Burns, Linda J ^a   De For, Todd E ^a   Cooley, Sarah ^a   Majhail, Navneet S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INCIDENCE; INFECTION; IRON OVERLOAD; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE;

EID: 84888074449     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-499772     Document Type: Article

References (34)

1. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588. (Pubitemid 46743431)
2. Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2009;146(3):310-316.
3. Mahindra A, Sobecks R, Rybicki L, et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplant. 2009;44(11):767-768.
4. Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopoietic cell transplantation. Bone Marrow Transplant. 2008;41(12):997-1003. (Pubitemid 352034174)
5. Kataoka K, Nannya Y, Hangaishi A, et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):195-204.
6. Meyer SC, O'Meara A, Buser AS, Tichelli A, Passweg JR, Stern M. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(3):440-444.
7. Bazuaye GN, Buser A, Gerull S, Tichelli A, Stern M. Prognostic impact of iron parameters in patients undergoing allo-SCT. Bone Marrow Transplant. 2012;47(1):60-64.
8. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89(3):739-761. (Pubitemid 27121266)
9. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573. (Pubitemid 24265698)
10. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008;14(7):790-794. (Pubitemid 351773155)
11. Armand P, Sainvil MM, Kim HT, et al. Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012;87(6):569-572.
12. * mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465. (Pubitemid 41129616)
13. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861. (Pubitemid 40070775)
14. Majhail NS, DeFor TE, Lazarus HM, Burns LJ. Iron-overload after autologous hematopoietic cell transplantation. Leuk Res. 2009;33(4):578-579.
15. Majhail NS, Lazarus HM, Burns LJ. A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant. 2010;16(6):832-837.
16. Armand P, Sainvil MM, Kim HT, et al. Pretransplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013;48(1):146-147.
17. Foley B, Cooley S, Verneris MR, et al. NK cell education after allogeneic transplantation: dissociation between recovery of cytokineproducing and cytotoxic functions. Blood. 2011;118(10):2784-2792.
18. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919. (Pubitemid 41510773)
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
20. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
21. Bearman SI. The syndrome of hepatic venoocclusive disease after marrow transplantation. Blood. 1995;85(11):3005-3020.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16(8):901-910. (Pubitemid 27198953)
24. Cox DR. Regression models and life tables. J R Stat Soc Series B. 1972;34:187-202.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
26. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
27. Wermke M, Schmidt A, Middeke JM, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res. 2012;18(23):6460-6468.
28. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant. 1999;24(3):307-312. (Pubitemid 29377872)
29. McKay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant. 1996;17(1):63-66. (Pubitemid 26031892)
30. Morado M, Ojeda E, Garcia-Bustos J, et al. BMT: Serum Ferritin as Risk Factor for Veno-occlusive Disease of the Liver. Prospective Cohort Study. Hematology. 2000;4(6):505-512. (Pubitemid 30217860)
31. Altes A, Remacha AF, Sarda P, et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant. 2004;34(6):505-509. (Pubitemid 39264040)
32. Jastaniah W, Harmatz P, Pakbaz Z, Fischer R, Vichinsky E, Walters MC. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer. 2008;50(2):319-324.
33. Porto G, De Sousa M. Iron overload and immunity. World J Gastroenterol. 2007;13(35):4707-4715. (Pubitemid 47455561)
34. Cherayil BJ. Iron and immunity: immunological consequences of iron deficiency and overload. Arch Immunol Ther Exp (Warsz). 2010;58(6):407-415.